This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in Travel & Tourism ETFs Now?
by Neena Mishra
Travel stocks could benefit from pent-up demand as we return to normal
ETFs to Play the Reopening Trade on Merck's Oral Antiviral Pill News
by Sweta Jaiswal, FRM
Let's take a look at ETFs that are well-poised to gain as the reopening of the U.S. economy may pick up further pace following Merck's announcement.
What September Lull? 4 ETF Areas That Are Up At Least 10%
by Sanghamitra Saha
While the month of September has been downbeat for Wall Street on Evergrande crisis and rising rate worries, these ETF areas surged on their own sector strength.
5 Top ETF Stories of Nine Months of 2021
by Sweta Killa
We discuss some of the hot events of the first nine months of this year that influenced the market in a big way.
5 Best-Performing ETF Areas of Last Week
by Sanghamitra Saha
Key indexes of Wall Street overlooked the Evergrande-related tensions and ended the week on a positive note.
Travel & Tourism ETFs to Gain on Easing U.S. Travel Restriction
by Sanghamitra Saha
The United States will likely loosen travel restrictions for international visitors who are vaccinated against Covid-19 in November. This should boost travel ETFs
ETFs to Win & Lose as Delta Variant Cases Surge
by Sweta Killa
We have highlighted some ETFs from various corners of the space that are expected to win and lose from the surging pandemic.
SS&C ALPS Advisors Launches Travel ETF (JRNY)
by Sweta Jaiswal, FRM
The travel industry has been getting the much-needed boost from the reopening of the U.S. economy, accelerated coronavirus vaccine rollout initiatives and solid fiscal stimulus support.
ETFs in Focus on Airlines' Slowdown Warnings
by Sweta Killa
The slew of revenue warnings comes with signs of recovery, thereby leading to spike in airline stocks.
ETFs to Rise on Full FDA Approval for Pfizer COVID-19 Vaccine
by Sweta Jaiswal, FRM
Let's look at the ETFs that are well-poised to gain as Comirnaty's full FDA approval is likely to drive the vaccination rate.